Compugen to Showcase Groundbreaking Research in Cancer Immunotherapy
Compugen Ltd. (Nasdaq: CGEN), a leading force in clinical-stage cancer immunotherapy, has announced an exciting opportunity to present at the upcoming Single Cell Genomics 2025 Conference. This event, scheduled for September 15-17, highlights advancements in genomics and how it intertwines with cancer research.
Understanding Cancer Biology Through Innovation
This presentation is set to illuminate how Compugen's innovative computational framework enables a deeper understanding of the spatial dynamics within complex cancer biology. Such insights are pivotal for informing drug discovery efforts and crafting therapeutic strategies that aim to enhance patient care.
Details of the Research Presentation
The spotlight will be on their research titled "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer," presented by Dr. Roy Granit, who serves as Senior Director and Head of Computational Discovery at Compugen.
Event Specifics
The presentation will occur on September 15, at 2:10 PM CET, and poster ID P035 will be featured, showcasing groundbreaking findings that may reshape approaches to treatment.
Future of Cancer Treatment: Compugen's Commitment
Compugen is not just attending a conference; it is actively contributing to the future of cancer treatment. Their commitment to innovative therapeutic development stems from their advanced Unigen™ computational discovery platform, which assists in pinpointing potential drug targets and identifying essential biological pathways.
Innovative Products in Development
Currently, Compugen has two primary product candidates undergoing Phase 1 trials: COM701, an anti-PVRIG antibody that is positioned as a potential first-in-class treatment, and COM902, targeting TIGIT with promising applications in solid tumor treatment. Moreover, the company collaborates with AstraZeneca for the development of a bispecific antibody, Rilvegostomig, leveraging resources from their anti-TIGIT portfolio.
Exploring Tomorrow's Innovations
With further developments such as GS-0321, a first-in-class anti-IL-18 binding protein antibody in Phase 1, and various early-stage immuno-oncology programs, Compugen's pipeline reflects a strong potential to revolutionize cancer immunotherapy.
Global Reach of Compugen
Based in Israel and with a thriving office in San Francisco, CA, Compugen's influence extends globally, connecting with a wide range of stakeholders in the healthcare and scientific communities. Their journey is emblematic of a focused mission: to unlock new avenues in immunotherapy.
Engagement and Communication
Compugen remains committed to transparent communication with its stakeholders. For inquiries, Dr. Yvonne Naughton serves as the Vice President and Head of Investor Relations. She can be contacted directly via telephone for detailed discussions about the company’s advancements and research efforts.
Frequently Asked Questions
What is Compugen's primary focus?
Compugen focuses on cancer immunotherapy, using AI/ML to discover new drug targets and biological pathways.
When will Compugen present its research?
Compugen will present at the Single Cell Genomics 2025 Conference from September 15-17.
Who is leading the research presentation?
Dr. Roy Granit, Senior Director and Head of Computational Discovery, will lead the presentation.
What is the significance of the research being presented?
The research enhances understanding of the spatial context of cancer biology, aiding drug discovery and therapeutic strategies.
How can stakeholders learn more about Compugen?
Stakeholders can reach out to Dr. Yvonne Naughton for inquiries regarding the company’s developments and research outcomes.
